Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 patients

Abstract Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive biomarker of response to immune checkpoint blockade in non‐small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD‐L1 expression, clinicopathological features, and th...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Gonzalo Ruiz, Diego Enrico, Yamil D. Mahmoud, Alan Ruiz, María Florencia Cantarella, Laura Leguina, Mariana Barberis, Asunción Beña, Esteban Brest, Solange Starapoli, Andrea Mendoza Bertelli, Florencia Tsou, Carmen Pupareli, María Pía Coppola, Alejandra Scocimarro, Susana Sena, Patricio Levit, Aldo Perfetti, Enrique Aman, María Romina Girotti, Oscar Arrieta, Claudio Martín, Rubén Salanova
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-04-01
Serie:	Thoracic Cancer
Soggetti:	programmed death‐ligand 1 (PD‐L1) non‐small cell lung cancer (NSCLC) immunohistochemistry (IHC) driver mutations genomic alterations
Accesso online:	https://doi.org/10.1111/1759-7714.15244
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!